# Abbisko Therapeutics

Source: https://onco.cc/companies/abbisko/  
OnCo record `abbisko` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Abbisko is a Shanghai biotech listed in Hong Kong whose CSF-1R inhibitor pimicotinib met its phase 3 endpoint in tenosynovial giant cell tumour, a rare joint tumour, and is licensed to Merck KGaA.

## Summary

Abbisko Therapeutics, based in Shanghai and listed in Hong Kong, develops small-molecule kinase inhibitors. Its lead drug pimicotinib (ABSK021), a selective CSF-1R inhibitor, met the primary endpoint of the phase 3 MANEUVER trial in tenosynovial giant cell tumour and is partnered with Merck KGaA outside China; FGFR4 and pan-FGFR inhibitors follow in liver and urothelial cancer. Its trials are registered on ClinicalTrials.gov under Abbisko as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Abbisko Therapeutics Co, Ltd; 和誉生物
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.abbisko.com

## Sources

- Official website: https://www.abbisko.com
- ClinicalTrials.gov: trials led by Abbisko Therapeutics Co, Ltd: https://clinicaltrials.gov/search?lead=Abbisko%20Therapeutics%20Co%2C%20Ltd
- Wikidata: https://www.wikidata.org/wiki/Q140045781

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Tenosynovial giant cell tumour (TGCT)](https://onco.cc/cancers/tenosynovial-giant-cell-tumour/)
- targets: [CSF1R](https://onco.cc/targets/csf1r/)
- drugs: [ABSK061](https://onco.cc/drugs/absk061/), [Pimicotinib](https://onco.cc/drugs/pimicotinib/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [A Phase 2 Clinical Study of ABSK061 and ABSK043](https://onco.cc/trials/nct06632262/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib](https://onco.cc/trials/nct06668103/), [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib](https://onco.cc/trials/nct07164170/), [A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct06111274/), [A Phase 2 Study of ABSK043 Combined With Osimertinib](https://onco.cc/trials/nct07710612/), [A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )](https://onco.cc/trials/nct07417189/), [ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression](https://onco.cc/trials/nct07327034/), [Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)](https://onco.cc/trials/nct05804045/)

---
JSON: https://onco.cc/api/v1/entities/abbisko.json